Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/29943
Başlık: Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta
Yazarlar: Wranke, Anika
Hardtke, Svenja
Heidrich, Benjamin
Dalekos, George
Yalçın, Kendal
Tabak, Fehmi
Çakaloğlu, Yılmaz
Akarca, Ulus S.
Lammert, Frank
Haeussinger, Dieter
Mueller, Tobias
Woebse, Michael
Manns, Michael P.
Idilman, Ramazan
Cornberg, Markus
Wedemeyer, Heiner
Yurdaydın, Cihan
Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.
Gürel, Selim
EYK-5719-2022
7003706434
Anahtar kelimeler: Chronic hepatitis
Clinical outcome
Delta virus
Endpoint
Hepatitis D
Interferon therapy
Virus-RNA
Infection
Prevalence
Kinetics
Alpha-2b
Flares
Need
Gastroenterology & hepatology
Infectious diseases
Virology
Yayın Tarihi: 24-Tem-2020
Yayıncı: Wiley
Atıf: Wranke, A. vd. (2020). "Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta". Journal of Viral Hepatitis, 27(12), 1359-1368.
Özet: Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis. PEG-interferon alpha-2a (PEG-IFNα-2a) is the only effective treatment but its long-term clinical impact is unclear. The aim of this study was to investigate the long-term outcome after 48 weeks of pegylated interferon alpha-2a therapy. We performed a retrospective follow-up study of the Hep-Net-International-Delta-Hepatitis-Intervention-Study 1 (HIDIT-I trial). Patients had received 48 weeks of treatment with either PEG-IFNα-2a plus adefovir dipivoxil (ADV) (Group I), PEG-IFNα-2a alone (Group II) or adefovir dipivoxil alone (Group III). Liver-related complications were defined as liver-related death, liver transplantation, liver cancer and hepatic decompensation defined as development of Child-Pugh scores B or C or an increase in Model for End-stage Liver Disease (MELD) scores of five or more points in relation to baseline values. Patients were considered for further analysis when they were retreated with PEG-IFNα-2a. Follow-up data (at least 1 visit beyond post-treatment week 24) were available for 60 patients [Group I, (n = 19), Group II (n = 20), Group III (n = 21)]. Mean time of follow-up was 8.9 (1.6 - 13.4) years. 19 patients were retreated with IFN-based therapy: 42% (n = 8) in PEG-IFNα-2a arms and 58% (n = 11) in the adefovir only arm. Clinical complications on long-term follow-up occurred in 17 patients and were associated with nonresponse to therapy and baseline cirrhosis. The annual event-free survival rate in patients with cirrhosis vs noncirrhotic patients at year 5 and 10 was 70% vs 91% and 35% vs 76%. Long-term follow-up of a large randomized clinical trial suggests that off-treatment HDV RNA response to PEG-IFNα-2a treatment leads to improved clinical long-term outcome.
URI: https://doi.org/10.1111/jvh.13366
https://onlinelibrary.wiley.com/doi/10.1111/jvh.13366
http://hdl.handle.net/11452/29943
ISSN: 1352-0504
Koleksiyonlarda Görünür:PubMed
Scopus
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Gürel_vd_2020.pdf629.52 kBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons